Trump Administration Announces Deal with AstraZeneca to Reduce US Drug Prices

Strategic Insights -

US President Donald Trump has announced a deal with AstraZeneca PLC that will lead to significantly lower domestic drug prices in exchange for granting the pharma giant tariff relief. The agreement requires AstraZeneca to charge "Most Favored Nation" pricing to Medicaid, the US health insurance programme for low-income Americans, and to participate in a website called TrumpRx that would allow direct purchasing at reduced prices.

Key Takeaways:

  • The deal between AstraZeneca and the Trump administration requires the pharma giant to charge "Most Favored Nation" pricing to Medicaid, matching the lowest price offered in other wealthy nations.
  • AstraZeneca has agreed to participate in a website called TrumpRx that would allow direct purchasing at reduced prices.
  • The company will also provide "massively" discounted drugs for lung disease, according to Mehmet Oz, the Trump-appointed leader of the Centers for Medicare & Medicaid Services.
  • In exchange, the Trump administration has agreed to a three-year delay on new tariffs on AstraZeneca, which had previously announced plans to invest USD50 billion in the US in response to looming tariff threats.
  • This agreement comes on the heels of a similar accord announced last month with Pfizer Inc, which also included three-year tariff relief.
  • Shares of Pfizer and other drugmakers surged after the September 30 announcement, suggesting they are not viewed as a major drag on profit.

Statistics:

  • USD50 billion: The amount AstraZeneca had previously announced plans to invest in the US in response to looming tariff threats.
  • 3 years: The duration of the tariff relief granted to AstraZeneca as part of the deal.
  • 15: The number of leading drugs that will be subject to pricing negotiations in November under legislation signed by former president Joe Biden in 2022.
  • November: The month in which pharmaceutical companies will engage in pricing negotiations on 15 leading drugs.

Sources:

  • AFP (No date)
  • White House (No date)